Polycystic Ovary Syndrome (PCOS)
Comprehensive Clinical Overview: Diagnosis, Management, and Evidence-Based Approaches
Evidence-Based Medicine
Professor Mykhailo Medvediev
Based on international guidelines and evidence-based medicine principles
Introduction
PCOS: A Common Endocrinopathy
Prevalence & Impact
PCOS affects 5-10% of women of reproductive age, making it one of the most common endocrine disorders. It is the leading cause of infertility in women and has significant lifelong health implications.
The syndrome encompasses reproductive, metabolic, and psychological manifestations that require comprehensive management.
Clinical Heterogeneity
PCOS presents with variable features including:
  • Menstrual irregularity (oligomenorrhea/amenorrhea)
  • Hyperandrogenism (hirsutism, acne)
  • Polycystic ovarian morphology
  • Metabolic dysfunction
Reference: Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Hum Reprod 2004;19:41
Diagnostic Criteria
Rotterdam Criteria for PCOS Diagnosis
01
Two of Three Criteria Required
Diagnosis requires presence of at least 2 of 3 features after excluding other etiologies
02
Oligo/Anovulation
Irregular menstrual cycles: <9 periods per year or cycles >35 days apart
03
Hyperandrogenism
Clinical (hirsutism, acne) and/or biochemical (elevated testosterone)
04
Polycystic Ovaries
≥12 follicles (2-9mm) or ovarian volume >10mL on ultrasound
Reference: Rotterdam ESHRE/ASRM. Fertil Steril 2004;81:19
Clinical Features
Menstrual Dysfunction in PCOS
Patterns of Menstrual Irregularity
Oligomenorrhea is the most common presentation, typically beginning in the peripubertal period. Women experience fewer than 9 menstrual periods per year.
Amenorrhea (absence of menses for ≥3 months) occurs less frequently but indicates more severe ovulatory dysfunction.
Menstrual patterns often improve after age 40, though metabolic risks persist throughout life.
Key Statistics
• 75% have oligomenorrhea
• 20% have amenorrhea
• 5% have regular cycles
• Menarche may be delayed

Important: Women with oligomenorrhea can ovulate intermittently and may achieve pregnancy unexpectedly. Contraception counseling is essential.
Reference: Legro RS et al. J Clin Endocrinol Metab 2013;98:4565
Hyperandrogenism: Clinical Manifestations
Hirsutism
Excess terminal hair in male pattern distribution. Ferriman-Gallwey score ≥8 indicates hirsutism in general US population (varies by ethnicity: ≥2-3 in Asian, ≥9-10 in Mediterranean populations).
Acne Vulgaris
Moderate to severe inflammatory acne affects 60% of adolescents with PCOS (2.8-fold higher than controls). Persistent acne resistant to topical therapy suggests hyperandrogenemia.
Androgenetic Alopecia
Female pattern hair loss affecting the crown, or male pattern affecting fronto-temporal regions. Less common in adolescents but significant when present.
Reference: Martin KA et al. J Clin Endocrinol Metab 2018;103:1233
Metabolic Features
Metabolic Syndrome in PCOS
40-85%
Obesity Prevalence
Overweight or obese compared to age-matched controls
30-70%
Insulin Resistance
Present in lean (30%) and obese (70%) women with PCOS
25%
Metabolic Syndrome
Three times more common than expected for age and BMI
Cardiovascular Risk Factors
  • Abdominal obesity (waist ≥88cm)
  • Hyperglycemia/glucose intolerance
  • Elevated triglycerides
  • Low HDL cholesterol
  • Hypertension
Long-term Complications
  • Type 2 diabetes (10% by age 40)
  • Cardiovascular disease risk
  • Obstructive sleep apnea
  • Hepatic steatosis (MASLD)
  • Endometrial hyperplasia/cancer
Reference: Randeva HS et al. Endocr Rev 2012;33:812
Insulin Resistance: Clinical Manifestations
Acanthosis Nigricans
Dark, velvety skin patches in body folds (neck, axillae, groin). Key indicator of insulin resistance, may precede other PCOS symptoms.
Glucose Intolerance
Impaired glucose tolerance in 30-40% of women with PCOS. Significant pancreatic beta cell dysfunction similar to type 2 diabetes.
Dyslipidemia
Related to obesity, insulin resistance, and hyperandrogenism. Prevalence varies but increases with metabolic severity.

Clinical Pearl: Low SHBG is a predictor of type 2 diabetes development and indicates more severe PCOS phenotype with increased biologically active testosterone.
Reference: Legro RS et al. Fertil Steril 1999;84:165
Diagnostic Evaluation
When to Suspect PCOS
1
Clinical Presentation
Irregular menses + hyperandrogenic symptoms (acne, hirsutism, hair loss) in reproductive-age women
2
Risk Assessment
Presence of obesity, family history of diabetes, or metabolic syndrome features
3
Early Diagnosis
High index of suspicion important for quality of life and cardiovascular risk management
Common Delays in Diagnosis
Studies show poor diagnosis experience:
  • Nearly 50% see ≥3 health professionals before diagnosis
  • One-third wait >2 years for diagnosis
  • Only 16% satisfied with health information received
Importance of Early Recognition
Early diagnosis enables:
  • Prevention of endometrial hyperplasia
  • Management of metabolic risks
  • Treatment of distressing symptoms
  • Fertility preservation strategies
Reference: Gibson-Helm M et al. J Clin Endocrinol Metab 2017;102:604
Biochemical Testing Strategy
1
First-Line Tests
Total Testosterone: LC-MS/MS preferred (upper limit 45-60 ng/dL). Immunoassays unreliable in women.
17-Hydroxyprogesterone: Early morning, follicular phase to exclude NCCAH (especially in high-risk ethnicities).
2
Exclude Other Causes
hCG, Prolactin, TSH, FSH: Rule out pregnancy, hyperprolactinemia, thyroid disease, and premature ovarian insufficiency.
3
Optional Tests
Free Testosterone: Only if measured by equilibrium dialysis or calculated from total testosterone + SHBG.
DHEAS: Reserved for severe hyperandrogenism/virilization cases.

Important: Do not measure androgens while on oral contraceptives, metformin, or spironolactone. Stop medications 4-6 weeks before testing.
Reference: Martin KA et al. J Clin Endocrinol Metab 2018;103:1233
Transvaginal Ultrasound Criteria
Rotterdam Criteria (2003)
≥12 follicles (2-9mm diameter) in either ovary and/or ovarian volume >10mL
Limitations: Over 50% of normal-cycling women may meet this threshold with modern high-resolution ultrasound
Updated Recommendations (2018)
International guidelines suggest ≥20 follicles per ovary when using transducers ≥8 MHz frequency
Age considerations: Follicle number decreases with age; age-based criteria proposed
When Ultrasound is NOT Needed
If patient has both oligomenorrhea AND hyperandrogenism with other causes excluded, diagnosis is confirmed without imaging
Incidental Findings
Polycystic ovaries on imaging without clinical features do NOT indicate PCOS. No further evaluation needed.
Reference: Teede HJ et al. Fertil Steril 2018;110:364
Differential Diagnosis
Excluding Other Causes of Hyperandrogenism
Nonclassic CAH
21-hydroxylase deficiency: 4.2% of hyperandrogenic women worldwide. Morning 17-OHP >200 ng/dL suggests diagnosis. Prevalence: 1:27 in Ashkenazi Jews, 1:40 Hispanic, 1:50 Slavic.
Thyroid Dysfunction
Hypothyroidism and hyperthyroidism cause menstrual irregularity. Screen with TSH. Hypothyroidism may cause coarse hair mistaken for hirsutism.
Hyperprolactinemia
Prolactin >25 ng/mL usually has identifiable cause. 40% of hyperprolactinemic women have hyperandrogenism; 85% with hyperandrogenism have galactorrhea.
Reference: Azziz R et al. Fertil Steril 2009;91:456
Severe Hyperandrogenism: Red Flags
Virilization Signs
Deepening voice, clitoromegaly, increased muscle mass, temporal hair recession, rapid progression of hirsutism
Testosterone Levels
Total testosterone >150 ng/dL (5.2 nmol/L) requires immediate evaluation for androgen-secreting tumors
DHEAS Elevation
Markedly elevated DHEAS suggests adrenal source. Extremely high levels may indicate adrenocortical carcinoma
Ovarian Tumors
Rare but serious cause of hyperandrogenism. More than half are malignant. Typically present with:
  • Rapid onset symptoms
  • Virilization
  • Palpable pelvic mass
  • Markedly elevated testosterone
Ovarian Hyperthecosis
Severe insulin resistance with ovarian stromal hyperplasia. More common in postmenopausal women but can occur in reproductive years. Requires surgical diagnosis.
Reference: Derksen J et al. N Engl J Med 1994;331:968
Cardiometabolic Assessment
Comprehensive Metabolic Screening
01
Initial Assessment
Blood pressure, BMI, waist circumference at diagnosis and ongoing monitoring
02
Lipid Profile
Fasting lipid panel at initial diagnosis to assess cardiovascular risk
03
Glucose Metabolism
2-hour OGTT preferred (fasting and 2-hour glucose). If not feasible: fasting glucose + HbA1c
04
Follow-up Screening
Normal glucose tolerance: rescreen every 2 years. Impaired glucose tolerance: annual screening for diabetes

Rationale for OGTT: Fasting glucose alone lacks sensitivity to detect impaired glucose tolerance or early type 2 diabetes present in substantial numbers of women with PCOS.
Reference: Salley KE et al. J Clin Endocrinol Metab 2007;92:4546
Additional Screening Recommendations
Obstructive Sleep Apnea
Screen for symptoms:
  • Snoring
  • Excessive daytime sleepiness
  • Morning headaches
If positive: polysomnography and sleep medicine referral
Depression & Anxiety
Use validated screening tools:
  • PHQ-9 for depression
  • GAD-7 for anxiety
  • PHQ-2 as brief alternative
Ensure referral pathway for positive screens
Hepatic Steatosis
Consider screening when suspected:
  • Elevated liver enzymes
  • Metabolic syndrome
  • Severe obesity
MASLD common in PCOS, related to visceral fat and hyperandrogenism
Reference: Teede HJ et al. Fertil Steril 2018;110:364
Psychosocial Impact of PCOS
17-50%
Depression Prevalence
Increased prevalence of depressive symptoms versus controls, even when matched for BMI
2.8x
Anxiety Risk
Higher rates of anxiety disorders compared to women without PCOS
21%
Major Depression
In adolescents with PCOS versus 3% in controls
Contributing Factors
  • Body image distress
  • Hirsutism and acne concerns
  • Infertility worries
  • Weight management challenges
  • Chronic disease burden
Associated Conditions
  • Eating disorders (binge eating)
  • Impaired quality of life
  • Possible autism spectrum disorders
  • ADHD in offspring
Reference: Dokras A et al. Fertil Steril 2018;109:888
Treatment Overview
Goals of PCOS Management
Menstrual Regulation
Restore regular cycles, prevent endometrial hyperplasia and cancer risk
Hyperandrogenism
Manage hirsutism, acne, and androgenetic alopecia
Metabolic Health
Reduce cardiovascular risk, prevent type 2 diabetes
Contraception
Prevent unwanted pregnancy in those not pursuing fertility
Fertility
Ovulation induction for those desiring pregnancy
Reference: Legro RS et al. J Clin Endocrinol Metab 2013;98:4565
Treatment Approach: Not Pursuing Pregnancy
First-Line: Combined Oral Contraceptives
COCs are mainstay of therapy for menstrual dysfunction, endometrial protection, hyperandrogenism management, and contraception. Start with 20 mcg ethinyl estradiol + norethindrone or norethindrone acetate.
Alternative: Progestin-Only Options
For women who cannot take COCs: cyclic progestin (MPA 5-10mg for 10-14 days every 1-2 months) or continuous progestin (norethindrone 0.35mg daily or levonorgestrel IUD).
Limited Role of Metformin
Metformin restores ovulatory menses in 30-50% but is second-line for endometrial protection. Not recommended for routine use except in glucose intolerance after lifestyle intervention failure.
Reference: Legro RS et al. J Clin Endocrinol Metab 2013;98:4565
Hirsutism Management
Pharmacologic Treatment of Hirsutism
1
Step 1: Start COC Monotherapy
Begin with COC containing 20 mcg ethinyl estradiol + norethindrone/norethindrone acetate. Lower androgenicity with similar VTE risk compared to levonorgestrel-containing COCs.
2
Step 2: Assess Response at 6 Months
Evaluate clinical improvement in hirsutism, acne, and menstrual regularity. Hair growth cycle requires 6 months for visible changes.
3
Step 3: Add Antiandrogen if Needed
If suboptimal response, add spironolactone 50-100mg twice daily. Ensure reliable contraception due to risk of feminization of male fetus.
4
Step 4: Consider Direct Hair Removal
Adjunctive mechanical methods: laser therapy, electrolysis, or eflornithine cream. Pharmacologic therapy does not eliminate existing hair.
Reference: Martin KA et al. J Clin Endocrinol Metab 2018;103:1233
Antiandrogen Therapy Options
Spironolactone (Preferred)
Mechanism: Aldosterone antagonist with antiandrogen effects
Dose: 50-100mg twice daily
Advantages: Well-studied, generally well-tolerated
Monitoring: Potassium, blood pressure
Contraindications: Pregnancy, renal insufficiency, hyperkalemia
Alternative Agents
Finasteride: 5-alpha reductase inhibitor, 2.5-5mg daily. Teratogenic - requires reliable contraception.
Cyproterone acetate: Available outside US, effective antiandrogen. Higher VTE risk.
Flutamide: NOT recommended due to hepatotoxicity risk.

Critical Safety Point: All antiandrogens are contraindicated in pregnancy due to risk of feminization of male fetus. Reliable contraception is mandatory. Never use antiandrogens as monotherapy in reproductive-age women.
Reference: Martin KA et al. J Clin Endocrinol Metab 2018;103:1233
COC Selection and VTE Risk Considerations
1
Lower VTE Risk Progestins
Norethindrone, norethindrone acetate, levonorgestrel, norgestimate have similar baseline VTE risk
2
Higher VTE Risk Progestins
Desogestrel, drospirenone, cyproterone acetate associated with possible higher VTE risk
3
Dose Considerations
Start with 20 mcg ethinyl estradiol. May increase to 30-35 mcg if needed for androgen suppression
4
Special Populations
Use caution in obese women (BMI ≥30) over age 40. Assess individual VTE risk factors before prescribing
Reference: Combined estrogen-progestin contraception guidelines, CDC US-MEC 2024
Weight Management
Lifestyle Modification: First-Line Therapy
Benefits of Weight Loss
Even modest weight loss (5-10% body weight) can result in:
  • Restoration of ovulatory cycles
  • Improved pregnancy rates
  • Decreased androgen levels
  • Improved insulin sensitivity
  • Reduced cardiovascular risk
Evidence Base
Short-term studies demonstrate metabolic and reproductive benefits, though response is variable. No specific diet type proven superior for PCOS.
Low-carbohydrate and standard diets show equal effectiveness for weight loss and metabolic improvements.
1
Diet
Calorie-restricted diet, no specific macronutrient composition required
2
Exercise
Regular physical activity improves ovulation and insulin sensitivity
3
Behavioral
Long-term lifestyle changes, not short-term dieting
Reference: Moran LJ et al. Cochrane Database Syst Rev 2011;CD007506
Pharmacologic Weight Loss Options
GLP-1 Receptor Agonists
Semaglutide and other GLP-1 agonists show similar weight loss efficacy in PCOS as in general population. Emerging as preferred pharmacologic option for obesity in PCOS.
Other Medications
Standard obesity medications (orlistat, phentermine-topiramate, naltrexone-bupropion) can be used. Approach similar to patients without PCOS.
Metformin
Limited role for weight loss. Modest effect (2-3 kg) compared to placebo. Not recommended as primary weight loss agent.
Bariatric Surgery
Effective option for severe obesity (BMI >35 kg/m²):
  • Significant weight loss
  • Restoration of ovulation (2.5x more likely than medical therapy)
  • Improved metabolic parameters
  • Resolution of PCOS features in many cases
Surgery Outcomes
Randomized trial: laparoscopic sleeve gastrectomy versus metformin + orlistat showed superior ovulation restoration at 52 weeks with surgery.
Long-term reproductive outcomes require further study.
Reference: Samarasinghe SNS et al. Lancet 2024;403:2489
Metabolic Management
Insulin Resistance and Diabetes Prevention
01
Lifestyle Intervention
First-line approach: diet, exercise, weight loss. Most effective strategy for preventing type 2 diabetes.
02
Glucose Monitoring
Regular screening with OGTT. Normal glucose tolerance: rescreen every 2 years. Impaired glucose tolerance: annual screening.
03
Pharmacologic Prevention
Metformin may be considered for diabetes prevention in high-risk patients (impaired glucose tolerance) who fail lifestyle interventions.
04
Diabetes Treatment
If type 2 diabetes develops, treat according to standard diabetes guidelines. PCOS does not alter diabetes management approach.

Important: Insulin resistance testing (HOMA-IR, fasting insulin) not necessary for PCOS diagnosis or treatment selection. No validated clinical test for insulin resistance exists.
Reference: American Diabetes Association Standards of Care
Metabolic Effects of COCs in PCOS
Insulin Sensitivity
COCs may decrease insulin sensitivity in healthy women, but effect generally not clinically significant.
In PCOS, studies show conflicting results: improvement, worsening, or no change in insulin sensitivity.
Compared to metformin: COCs may be less beneficial for insulin sensitivity but superior for androgen suppression and cycle control.
Cardiovascular Concerns
Theoretical concerns about CVD risk in PCOS due to underlying risk factors, but no PCOS-specific COC risk data available.
Standard COC contraindications apply. Assess individual risk factors (obesity, age, family history, smoking).
Benefits of menstrual regulation and endometrial protection generally outweigh metabolic concerns.
Reference: Godsland IF et al. J Clin Endocrinol Metab 1992;74:64
Dyslipidemia and Statin Therapy
First-Line: Lifestyle
Exercise and weight loss are primary interventions for dyslipidemia in PCOS. Same approach as general population.
Statin Efficacy
Statins effectively reduce LDL and triglycerides in PCOS. Meta-analysis of 244 women showed significant lipid improvements.
Limited Hormonal Effects
Small decrease in testosterone observed, but no improvements in menstrual regularity, ovulation, acne, hirsutism, or BMI.
Statin Indications in PCOS
  • Elevated LDL cholesterol
  • High cardiovascular risk score
  • Metabolic syndrome
  • Type 2 diabetes
Standard lipid treatment guidelines apply
Other Metabolic Conditions
Sleep Apnea: CPAP improves insulin sensitivity and blood pressure
MASLD: Weight loss and metformin improve hepatic function
Both conditions common in PCOS and require screening
Reference: Raval AD et al. Cochrane Database Syst Rev 2011;CD008565
Fertility Treatment
Ovulation Induction: First-Line Therapy
Letrozole (Preferred)
Aromatase inhibitor, now first-line for ovulation induction in PCOS. Higher live birth rates than clomiphene. Off-label use - must discuss with patient.
Clomiphene Citrate
Traditional first-line agent. FDA-approved for ovulation induction. 80% ovulation rate, 30-40% cumulative pregnancy rate. Efficacy decreases with higher BMI.
Metformin
Limited role in ovulation induction. Less effective than letrozole or clomiphene for live births. May reduce OHSS risk in IVF cycles.

Critical Point: Before starting letrozole, clinician must discuss that this use is not FDA-approved and that clomiphene is an available alternative. Document informed consent.
Reference: Legro RS et al. N Engl J Med 2014;371:119
Preconception Weight Loss Strategy
Evidence for Pretreatment
Post-hoc analysis of concurrent trials (OWL-PCOS and PPCOS II) showed:
  • 16-week lifestyle intervention: ~6.5% weight loss
  • Ovulation rate: 62% vs 45% (immediate clomiphene)
  • Live birth rate: 25% vs 10.2%
Pretreatment with COCs alone did not improve outcomes
Clinical Application
Recommend weight loss before ovulation induction in overweight/obese women with PCOS.
Exceptions: Older women (≥37 years) or diminished ovarian reserve - offer immediate or short (3-month) weight loss attempt.
Balance time to pregnancy with metabolic benefits
Reference: Legro RS et al. J Clin Endocrinol Metab 2016;101:2658
Second-Line Fertility Treatments
1
Gonadotropin Therapy
For clomiphene/letrozole-resistant cases. Ovulation rate 72%, pregnancy rate 45% with low-dose protocols. High risk of OHSS and multiple gestation. Requires experienced clinician.
2
Laparoscopic Ovarian Drilling
Surgical alternative to gonadotropins. Similar efficacy but lower risk of OHSS and high-order multiples. 80% ovulation rate (range 30-90%). Effects may persist for years.
3
In Vitro Fertilization
If other methods fail. Women with PCOS at high risk for OHSS. Frozen embryo transfer reduces OHSS risk compared to fresh transfer. Metformin may reduce OHSS risk in high-risk patients.

Laparoscopic Drilling Technique: 3-6 punctures per ovary, 40W coagulating current, 4 seconds per puncture. Technique not standardized but this approach reasonable based on dose-ranging studies.
Reference: Farquhar C et al. Cochrane Database Syst Rev 2012;CD001122
IVF Considerations in PCOS
OHSS Risk Management
Women with PCOS at high risk for ovarian hyperstimulation syndrome during IVF:
  • Use GnRH antagonist protocols
  • Consider GnRH agonist trigger
  • Freeze all embryos (no fresh transfer)
  • Consider metformin co-treatment
  • Low-dose gonadotropin stimulation
Metformin in IVF
Meta-analysis of 1123 women with PCOS undergoing IVF/ICSI:
  • OHSS rate: 10% with metformin vs 18% without (OR 0.43)
  • Benefit only significant in BMI >26 kg/m²
  • No improvement in pregnancy or live birth rates
Consider for overweight/obese women at high OHSS risk
Reference: Wu Y et al. JAMA Netw Open 2020;3:e2011995
Special Considerations
PCOS Phenotypes and Clinical Implications
1
Classic PCOS
Hyperandrogenism + Ovulatory dysfunction + Polycystic ovaries. Most severe phenotype with highest metabolic risk.
2
Hyperandrogenic Anovulatory
Hyperandrogenism + Ovulatory dysfunction (no PCO morphology). High metabolic and reproductive risk.
3
Ovulatory PCOS
Hyperandrogenism + Polycystic ovaries (regular cycles). Intermediate metabolic risk, may have fertility issues.
4
Mild PCOS
Ovulatory dysfunction + Polycystic ovaries (no hyperandrogenism). Mildest phenotype, controversial diagnosis.
Phenotype classification helps predict metabolic risk, fertility prognosis, and guide treatment intensity. Classic phenotype requires most aggressive metabolic screening and intervention.
Reference: Rotterdam ESHRE/ASRM. Hum Reprod 2004;19:41
PCOS in Adolescents: Diagnostic Challenges
Why Diagnosis is Difficult
  • Anovulatory cycles common in normal adolescents
  • Hirsutism still developing
  • Acne vulgaris very common
  • Polycystic ovary morphology frequent in normal teens
  • Androgen levels rise during anovulatory cycles
  • Lack of reliable adolescent androgen norms
Adolescent Diagnostic Criteria
International consensus requires:
  1. Persistent ovulatory dysfunction (menstrual abnormality for 1-2 years post-menarche)
  1. Clinical and/or biochemical hyperandrogenism
Provisional diagnosis: "At risk for PCOS" if <1-2 years duration. Treat symptomatically and reassess.

Important: Do not use polycystic ovary morphology as diagnostic criterion in adolescents. Ultrasound findings too common in normal teens to be specific.
Reference: Witchel SF et al. Horm Res Paediatr 2015
PCOS in Postmenopausal Women
Diagnostic Challenges
Difficult to establish diagnosis in postmenopausal women. Ovarian volume and follicle number decrease with age in all women. No well-established ultrasound criteria exist.
Presumptive Diagnosis
Based on well-documented history of oligomenorrhea and hyperandrogenism during reproductive years. PCOS morphology on ultrasound provides additional support.
New-Onset Symptoms
New or worsening hirsutism in postmenopausal women requires evaluation for ovarian hyperthecosis or androgen-secreting tumors. Always perform transvaginal ultrasound.
Persistent Metabolic Risks
  • Type 2 diabetes risk continues
  • Cardiovascular disease risk
  • Metabolic syndrome
  • Dyslipidemia
Continue metabolic screening and management
Reproductive Concerns Resolve
  • Menstrual irregularity no longer relevant
  • Endometrial cancer risk decreases
  • Hirsutism may improve with age
  • Ovarian morphology less important
Reference: Legro RS et al. J Clin Endocrinol Metab 2013;98:4565
Long-term Complications
Endometrial Cancer Risk
Mechanism of Risk
Chronic anovulation leads to:
  • Unopposed estrogen exposure
  • Endometrial proliferation
  • Hyperplasia development
  • Potential progression to carcinoma
Androgen excess may directly cause cystic glandular hyperplasia
Risk Magnitude
Systematic review and meta-analysis:
  • Increased endometrial cancer risk in PCOS
  • Risk highest in obese women
  • Young women (<54 years) particularly affected
  • Risk persists even with treatment
1
Prevention Strategy
Regular progestin exposure (COCs or cyclic progestin) to oppose estrogen effects
2
Screening Approach
No routine ultrasound screening in premenopausal women. Investigate abnormal bleeding promptly.
3
Patient Education
Counsel about importance of treatment adherence and reporting abnormal bleeding
Reference: Barry JA et al. Hum Reprod Update 2014;20:748
Cardiovascular Disease Risk
2-3x
Metabolic Syndrome
Three times more common in PCOS than expected for age and BMI
10%
Type 2 Diabetes
By age 40 in women with PCOS, with progressive deterioration over time
1.5-2x
CVD Events
Possible increased risk, though data inconclusive for hard cardiovascular endpoints
CVD Risk Factors in PCOS
  • Obesity (especially central)
  • Insulin resistance
  • Dyslipidemia
  • Hypertension
  • Chronic inflammation
  • Endothelial dysfunction
  • Sleep apnea
Risk Reduction Strategies
  • Weight loss and exercise
  • Smoking cessation
  • Blood pressure control
  • Lipid management
  • Diabetes prevention/treatment
  • Sleep apnea treatment
Reference: Twig G et al. N Engl J Med 2016;374:2430
Venous Thromboembolism Risk
Baseline PCOS Risk
Women with PCOS have 1.5-2 fold increased VTE risk compared to women without PCOS, independent of COC use. Risk increases with obesity and age.
COC-Associated Risk
COCs increase VTE risk in all users. Risk highest in first year of use and with higher estrogen doses. Obesity significantly amplifies risk.
Clinical Implications
Use caution prescribing COCs to obese women (BMI ≥30) over age 40. Assess individual risk factors. Consider progestin-only alternatives.
VTE Risk Factors
  • Obesity (BMI ≥30 kg/m²)
  • Age >40 years
  • Personal history of VTE
  • Family history of VTE
  • Thrombophilia
  • Immobility
  • Surgery
Risk Mitigation
  • Use lowest effective estrogen dose
  • Choose lower-risk progestins
  • Consider progestin-only options
  • Encourage weight loss
  • Regular risk reassessment
  • Patient education on VTE symptoms
Reference: CDC US Medical Eligibility Criteria for Contraceptive Use 2024
Emerging Therapies
Novel Therapeutic Approaches
GLP-1 Receptor Agonists
Semaglutide and other GLP-1 agonists show promise for weight loss and metabolic improvement in PCOS. Similar efficacy to general population. May improve ovulation and fertility outcomes.
Inositol Supplements
Myo-inositol investigated for insulin sensitivity and ovulation. However, systematic review of 30 trials showed no significant improvements in anthropometric, metabolic, or hormonal parameters. Not currently recommended.
Acupuncture
Often offered as adjunctive therapy. Evidence suggests no improvement in live birth rates when used alone or combined with clomiphene versus sham acupuncture. Not recommended as primary treatment.

Research Focus: Future studies needed on long-term outcomes of GLP-1 agonists in PCOS, including effects on fertility, pregnancy outcomes, and cardiovascular endpoints.
Reference: Cena H et al. J Clin Endocrinol Metab 2020;105:e2695
Complementary and Alternative Medicine
Commonly Used CAM Therapies
Many women with PCOS use complementary approaches:
  • Dietary supplements (inositol, vitamin D, omega-3)
  • Herbal remedies (spearmint tea, cinnamon)
  • Acupuncture
  • Mind-body practices (yoga, meditation)
  • Specific diets (low-carb, anti-inflammatory)
Evidence Base
Limited high-quality evidence for most CAM therapies in PCOS:
  • Vitamin D: conflicting results, may help if deficient
  • Inositol: no proven benefit in meta-analysis
  • Acupuncture: no improvement in live births
  • Spearmint tea: small studies suggest possible antiandrogen effect

Clinical Approach: Acknowledge patient interest in CAM. Discuss evidence limitations. Ensure CAM use doesn't delay proven therapies. Screen for potential drug interactions.
Reference: Fitz V et al. J Clin Endocrinol Metab 2024;109:1630
Patient-Centered Care
Improving Patient Experience and Satisfaction
Common Patient Concerns
Women with PCOS report dissatisfaction with care, long diagnostic delays, and inadequate information. Only 16% satisfied with educational materials received. Many see multiple providers before diagnosis.
Communication Strategies
Provide comprehensive education about PCOS as chronic condition. Discuss long-term health implications. Set realistic expectations for treatment timelines. Address psychological impact and body image concerns.
Multidisciplinary Approach
Coordinate care among endocrinology, gynecology, dermatology, nutrition, mental health, and reproductive medicine. Ensure continuity and avoid fragmented care.
Reference: Gibson-Helm M et al. J Clin Endocrinol Metab 2017;102:604
Shared Decision-Making in PCOS
Key Decision Points
Contraception vs. Fertility: Immediate reproductive goals guide treatment selection
COC Selection: Balance efficacy, side effects, and VTE risk based on individual factors
Weight Loss Approach: Lifestyle, medication, or surgery based on BMI and patient preference
Ovulation Induction: Letrozole vs. clomiphene, timing of treatment
Patient Preferences
Elicit patient priorities:
  • Most bothersome symptoms
  • Fertility timeline
  • Medication preferences
  • Risk tolerance
  • Treatment burden acceptance
  • Cost considerations
01
Present Options
Explain available treatments with evidence base
02
Discuss Trade-offs
Benefits, risks, and uncertainties of each option
03
Elicit Preferences
Understand patient values and priorities
04
Make Decision Together
Collaborative choice aligned with patient goals
Reference: Teede HJ et al. Fertil Steril 2018;110:364
Addressing Psychological Needs
Depression Screening
Use PHQ-9 or PHQ-2 at diagnosis and annually. Depression 17-50% more prevalent in PCOS. Ensure referral pathway for positive screens. Treatment approach same as general population.
Anxiety Assessment
GAD-7 scale for anxiety disorders. Higher rates in PCOS even when BMI-matched. Address body image concerns and fertility worries. Consider cognitive behavioral therapy.
Eating Disorders
Screen for disordered eating, particularly binge eating. More common in PCOS. May complicate weight management efforts. Requires specialized treatment approach.

Important: Screening alone does not improve outcomes. Must have process for referral and follow-up. Ideally, mental health services available at same site as PCOS care.
Reference: Dokras A et al. Fertil Steril 2018;109:888